You are here

Treatment Gap in People with Newly Diagnosed Epilepsy in Australia

Description 
Epilepsy is one of the most common serious chronic neurological disorders and is estimated to affect approximately 68 million people worldwide. Antiepileptic drugs are the mainstay of treatment and suppress seizure occurrence. Epilepsy treatment gap is a recognised public health issue in resource-poor countries where up to 80% of people with epilepsy do not receive appropriate treatment. However, recent preliminary study of 1,235 people with newly onset of unprovoked seizure(s) who were seen at a First Seizure Clinic between 1 May 1999 and 31 May 2016 and were prospectively followed for up to 16 years in Australia demonstrated nearly a quarter of the people newly diagnosed with epilepsy did not commence treatment. The causes of epilepsy treatment gap in resource-rich countries have not been well studied. We will review the clinical documents of these 1,235 individuals and extract additional information of neurologists’ and patients’ perspectives on commencing antiepileptic drug treatment. We will assess potential factors contributed to the treatment gap in the cohort.
Essential criteria: 
Minimum entry requirements can be found here: https://www.monash.edu/admissions/entry-requirements/minimum
Keywords 
Epilepsy, Antiepileptic Drug, Treatment Gap, Newly Diagnosed
School 
Central Clinical School
Available options 
Masters by Research
Honours
BMedSc(Hons)
Time commitment 
Full-time
Physical location 
AMREP
Co-supervisors 
Dr 
Zhibin Chen

Want to apply for this project? Submit an Expression of Interest by clicking on Contact the researcher.